Sac-TMT with toripalimab for first-line treatment of PD-L1 positive advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs, sacituzumab govitecan (Sac-TMT) and toripalimab, as a first treatment for women with advanced triple-negative breast cancer that tests positive for a protein called PD-L1. The goal is to see if this combination is safe and effective in shrinking or controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been diagnosed with advanced or metastatic triple-negative breast cancer (cancer that has spread or cannot be removed by surgery).
- Your cancer has not spread to the brain or spinal cord.
- You have not had any previous treatment for advanced disease.
- Your tumor tests positive for PD-L1 (a protein that may help cancer hide from the immune system).
- You are in good overall health (able to carry on daily activities, with a performance status of 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (sacituzumab tirumotecan and tagitanlimab) for people with advanced triple-negative breast cancer that has progressed after earlier treatments. The goal is to see if this combination can help control the cancer.
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
This trial tests if combining an immunotherapy drug (toripalimab) with targeted radiation (SBRT) can help people with triple-negative breast cancer that did not shrink after initial chemotherapy. It aims to improve outcomes before surgery.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted chemotherapy) and toripalimab (an immunotherapy)—as the first treatment for advanced triple-negative breast cancer. The goal is to see if this pair works better than standard treatments, and to look for biomarkers that might predict who benefits most.
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a new drug called Sacituzumab Tirumotecan (Sac-TMT) for people with early-stage, high-risk breast cancer that hasn't spread. The drug is given before surgery to see if it can shrink tumors and improve outcomes.
Hear when a new PD-L1 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.